Cerdulatinib

Drug Profile

Cerdulatinib

Alternative Names: Dual SYK/JAK inhibitor - Portola; PRT 2070; PRT-062070; RVT-502; RVT-502 - Dermavant Sciences

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Portola Pharmaceuticals
  • Developer Dermavant Sciences; NicOx; Portola Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Eye disorder therapies; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Phase I Skin disorders
  • No development reported Allergic rhinitis; Eye disorders

Most Recent Events

  • 23 Jun 2017 Interim efficacy data from a phase II trial in Haematological malignancies released by Portola Pharmaceuticals
  • 22 Jun 2017 Updated efficacy and adverse events data from a phase II trial in Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma were presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 15 Jun 2017 Interim adverse events data from a phase II trial in Haematological malignancies released by Portola Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top